Higher Starting Dose: The starting dose for Tirzepitide is 1.5 mg and increases over 16 weeks providing greater efficacy
Although the introduction of long-acting formulations has alleviated some concerns, the aversion to injections remains a barrier to broader market penetration
Expectedly, GPR120 agonism shows powerful anti-diabetic, anorexic, and hepatoprotective properties in multiple animal models (275, 284287), at least partially mediated by GLP-1 (288)
See NICE NG203 for further information
Supporting Longevity and Oxidative Stress Reduction: By improving cellular health and reducing oxidative stress, Glynac contributes to overall resilience and longevity, particularly for women experiencing hormonal fluctuations or stress
All peptides were provided by the Novo Nordisk Research Center Indianapolis, IN, USA or the Indiana Biosciences Research Institute, IN, USA (for drug development see Supplementary Information 1)